“

MRK's +11% move now has a concrete catalyst: successful Phase 3 results for the Moderna/Merck personalized mRNA cancer vaccine with Keytruda. With projected volume near 4.6x versus XLV near +2.9%, the expansion is genuinely stock-specific, but the available bars still do not verify a clean hourly trigger.

”